FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: Clinical implications and limitations

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 243-255

  Kayser, Sabine ^a   Levis, Mark J ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; FLT3 mutations; Mechanism of resistance; Molecular tailored therapy; Tyrosine kinase inhibitors

Indexed keywords

CD135 ANTIGEN; LESTAURTINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SORAFENIB; SUNITINIB; TANDUTINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CANCER THERAPY; DRUG POTENCY; DRUG SELECTIVITY; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ACUTE DISEASE; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; TANDEM REPEAT SEQUENCES;

EID: 84894255030     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.800198     Document Type: Review

References (97)

1. Mrózek K., Heerema NA, Bloomfield CD Cytogenetics in acute leukemia. Blood Rev 2004;18:115-136. (Pubitemid 38380667)
2. Marcucci G, Haferlach T, Dönner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-486.
3. Mardis ER, Ding L, Dooling D.J., et al Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
4. Kelly LM, Gilliland DG Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;3:179-198. (Pubitemid 35217435)
5. Welch JS, Ley TJ, Link D.C., et al The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-278.
6. Ding L, Ley TJ, Larson D.E., et al Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-510.
7. Hayakawa F, Towatari M, Kiyoi H., et al Tandem duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624-631. (Pubitemid 30102913)
8. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-3914.
9. Brandts CH, Sargin B, Rode M., et al Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005; 65:9643-9650. (Pubitemid 41541439)
10. Gilliland DG, Griffin JD The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-1542. (Pubitemid 34925124)
11. Nakao M, Yokota S, Iwai T., et al Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10:1911-1918. (Pubitemid 27019637)
12. Yokota S, Kiyoi H, Nakao M., et al Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various haematological malignancies: a study on a large series of patients and cell lines. Leukemia 1997, 11:1605-1609. (Pubitemid 27458595)
13. Fröhling S., Schlenk RF, Breitruck J, et al Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380. (Pubitemid 35434129)
14. Yamamoto Y, Kiyoi H, Nakano Y., et al Activating mutations of D835 within die activating loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-2439. (Pubitemid 32291491)
15. Abu-Duhier F.M., Goodeve AC, Wilson G.A., et al Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukemia. Br J Haematol 2001;113:983-988. (Pubitemid 32634768)
16. Reindl C, Bagrintseva K, Vempati S., et al Point mutations in the juxtamembrane domain of die FLT3 define a new class of activating mutations in AML. Blood 2006;107:3700-3707.
17. Kayser S, Schlenk RF, Londono M.C., et al Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated witii resistance to chemotherapy and inferior outcome. Blood 2009;114:2386-2392.
18. Breitenbuecher F, Schnittger S, Grundler R., et al Identification of a novel type of ITD mutations located in non-juxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009;113:4074-4077.
19. Schnittger S, Bacher U, Haferlach C., et al Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer 2012;51:910-924.
20. Breitenbuecher F, Markova B, Kasper S., et al A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in acute myeloid leukemia. Blood 2009;113:4063-4073.
21. Thiede C, Steudel C, Mohr B., et al Analysis of FLT3-activating mutations In 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335. (Pubitemid 34627197)
22. Whitman SP, Archer KJ, Feng L, et al Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-7239. (Pubitemid 32946520)
23. Meshinchi S, Stirewalt DL, Alonzo T.A., et al Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 2008; 111:4930-4933.
24. Stirewalt DL, Kopecky J, Meshinchi S., et al Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006;107:3724-3726.
25. Kusec R, Jaksic O, Ostojic S., et al More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML). Blood 2006; 108: 405-406. (Pubitemid 43990662)
26. Ponziani V, Gianfaldoni G, Mannelli F., et al The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia 2006;20:2074-2076. (Pubitemid 44614912)
27. Gale RE, Green C, Allen C., et al The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776-2784.
28. Borthakur G, Kantarjian H, Patel K.P., et al Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 2012;118:5819-5822.
29. Oyarzo MP, Lin P, Glassman A., et al Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004;122:348-358. (Pubitemid 39145539)
30. Gale RE, Hills R, Pizzey A.R., et al Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005;106:3768-3776. (Pubitemid 41739011)
31. Pratz KW, Sato T, Murphy K.M., et al FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115:1425-1432.
32. Seedhouse CH, Hunter HM, Lloyd-Lewis B, et al DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 2006;20:2130-2136. (Pubitemid 44782838)
33. Kayser S, Döhner K, Krauter J., et al Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications. Blood 2010;116(Suppl. 1): Abstract 909.
34. Schnittger S, Bacher U, Kern W., et al Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011;25:1297-1304.
35. Patel JP, Gönen M, Figueroa M.E., et al Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089.
36. Grundler R, Miething C, Thiede C., et al FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005;105:4792-4799. (Pubitemid 40807305)
37. Choudhary C, Schwäble J, Brandts C., et al AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 LTD mutations. Blood 2005;106:265-273. (Pubitemid 40967202)
38. Schlenk RF, Ganser A, Döhner K. Prognostic and predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia. ASCO Educ Book 2010:228-232.
39. Döhner H., Estey EH, Amadori S, et al Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
40. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008;45:17-21.
41. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116:5089-5102.
42. Stone RM, DeAngelo DJ, Klimek V, et al Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60. (Pubitemid 40053063)
43. Stone RM, Fischer T, Paquette R., et al Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26:2061-2068.
44. Smith BD, Levis M, Beran M, et al. Single-agentCEP-701, anovelFLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-3676. (Pubitemid 38596280)
45. Knapper S, Burnett AK, Littlewood T, et al A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-3270.
46. Levis M, Ravandi F, Wang E.S., et al Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294-3301.
47. Levis M, Pham R, Smith B.D., et al In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004; 104:1145-1150. (Pubitemid 39038036)
48. O'Farrell A.M., Foran JM, Fiedler W, et al An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9:5465-5476. (Pubitemid 37499464)
49. Fiedler W, Serve H, Dönner H, et al A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993. (Pubitemid 40170865)
50. Fiedler W, Kayser S, Kebenko M., et al Sunitinib and intensive chemotherapy in patients with acute myeloid leukemia and activating FLT3 mutations: results of the AMLSG 10-07 study (ClinicalTrails.gov No. NCT00783653). Blood 2012;120(Suppl. 1): Abstract 1483.
51. Zhang W, Konopleva M, Shi Y.X., et al Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-198. (Pubitemid 351480557)
52. Metzelder S, Schroeder T, Finck A., et al High activity of sorafenib in FLT3-rTD-positive acute myeloid leukemia (AML) synergizes with allo-immune effects to induce sustained responses. Leukemia 2012;26:2353-2359.
53. Pratz KW, Cho E, Levis M.J., et al A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010;24:1437-1444.
54. Ravandi F, Cortes JE, Jones D, et al Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-1862.
55. Serve H, Wagner R, Sauerland C., et al Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Blood. 2010;116(Suppl. 1): Abstract 333.
56. Krüger W.H., Hirt C, Kiefer T., et al Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib. Bone Marrow Transplant 2012;47:137-138.
57. Metzelder S, Wang Y, Wollmer E., et al Compassionate use of sorafenib in FLT3-rTD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-6571.
58. Sharma M, Ravandi F, Bayraktar U.D., et al Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011;17:1874-1877.
59. Zarrinkar PP, Gunawardane RN, Cramer M.D., et al AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-2992.
60. Cortes JE, Ghirdaladze D, Foran J.M., et al Phase I AML study of AC220, a potent and selective second generation FLT3 receptor tyrosine kinase inhibitor. Blood 2008;112(Suppl. 1): Abstract 767.
61. Cortes JE, Perl AE, Dombret H, et al Final results of a phase 2 open-label, monotherapy efficacy and safety of quizartinib (AC220) in patients a 60 years of age with FLT3ITD positive or negative relapsed/ refractory acute myeloid leukemia. Blood 2012;120(Suppl. 1): Abstract 48.
62. Levis MJ, Perl AE, Dombret H, et al Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood. 2012;120(Suppl. 1): Abstract 673.
63. Schlenk RF, Döhner K, Krauter J., et al Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918. (Pubitemid 351620111)
64. Brunet S, Labopin M, Esteve J. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012;30:735-741.
65. DeZern AE, Sung A, Kim S., et al Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011;17:1404-1409.
66. Bornhäuser M., Illmer T, Schaich M., et al Improved outcome after stem cell transplantation in FLT3/ITD-positive AML. Blood 2007;109:2265-2266.
67. Labouré G, Dulucq S, Labopin M, et al. Potent graft-versus- leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. Biol Blood Marrow Transplant 2012;18:1845-1850.
68. Doubek M, Muzfk J, Szotkowski T., et al Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). Neoplasma 2007;54:89-94.
69. Gale R, Hills R, Kottaridis P., et al No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005;106:3658-3665. (Pubitemid 41609208)
70. Sengsayadeth SM, Jagasia M, Engelhardt B.G., et al Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 2012; 47:1535-1537.
71. Pratcorona M, Brunet S, Nomdedéu J, et al Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013;121:2734-2738.
72. Kayser S, Schlenk RF, Krauter J, et al Prognostic impact of mutant to wild-type ratio and insertion site in acute myeloid leukemia with FLT3 internal tandem duplication. Blood 2012;120(Suppl. 1): Abstract 785.
73. Smith CC, Wang Q, Chin C.S., et al Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012;485:260-263.
74. Alvarado Y, Kantarjian HM, Ravandi F, et al FLT3 inhibitor treatment in FLT3-mutated AML is associated with development of secondary FLT3-TKD mutations. Blood 2011;118(Suppl. 1): Abstract 1493.
75. Heidel F, Solem FK, Breitenbuecher F, et al Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006;107:293-300. (Pubitemid 43053554)
76. Smith CC, Shah NP Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program 2011:121-127.
77. von Bubnoff N., Engh RA, Aberg E, et al FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69:3032-3041.
78. Williams AB, Nguyen B, Li L., et al Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013;27: 48-55.
79. Galanis A, Rajkhowa T, Muralidhara C., et al Crenolanib: a next generation FLT3 inhibitor. Cancer Res 2012;72(Suppl. 1): Abstract 3660.
80. O'Hare T., Shakespeare WC, Zhu X, et al AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-412.
81. Zirm E, Spies-Weisshart B, Heidel F., et al Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 2012;157: 483-492.
82. Smith CC, Lasater EA, Zhu X, et al Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013, 121:3165-3171.
83. Talpaz M, Shah NP, Deinlnger M.W., et al Ponatinib in patients with acute myeloid leukemia (AML): preliminary findings from a phase I study in hematologic malignancies. J Clin Oncol 2011;29(Suppl.): Abstract 6518.
84. Smith CC, Perl AE, Lasater E, et al PLX3397 is an investigational selective FLT3 inhibitor that retains activity against the clinically-relevant FLT3-ITD/F691L "gatekeeper" mutation in vitro. Blood 2011;118(Suppl. 1): Abstract 764.
85. Zhou J, Bi C, Janakakumara J.V., et al Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009;113:4052-4062.
86. Piloto O, Wright M, Brown P., et al Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007;109:1643-1652. (Pubitemid 46239599)
87. Parmar A, Marz S, Rushton S., et al Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res 2011;71:4696-4706.
88. Yang X, Sexauer A, Levis MJ Persistent ERK activation in bone marrow blasts may account for the difference in bone marrow versus peripheral blood response to FLT3 inhibition in FLT3/ITD AML. Blood 2011;118(Suppl. 1): Abstract 736.
89. Weisberg E, Liu Q, Nelson E., et al Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multl-targeted inhibitors, and JAK inhibitors. Leukemia 2012;26:2233-2244.
90. Sato T, Yang X, Knapper S., et al FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286-3293.
91. Levis M, Brown P, Smith B.D., et al Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006;108:3477-3483.
92. Fischer T, Stone RM, Deangelo D.J., et al Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-4345.
93. DeAngelo DJ, Stone RM, Heaney M.L., et al Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-3681. (Pubitemid 44864544)
94. DeAngelo DJ, Stone RM, Heaney M.L., et al Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood 2004;104(Suppl. 1): Abstract 496.
95. DeAngelo D, Amreln P, Kovacsovics T., et al Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 2006;108(Suppl. 1): Abstract 158.
96. Knapper S, White P, Levis M.J., et al The efficacy of the FLT3 inhibitor lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA) and is unaffected by rising FLT ligand levels: an update of the NCRIAML15 & 17 trials. Blood 2011;118(Suppl. 1): Abstract 421.
97. Faivre S, Delbaldo C, Vera K., et al Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. (Pubitemid 46630490)